{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-067774","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2023-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.021577+00:00","generated_at":"2026-06-07T18:47:02.232569+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CRISPR Therapeutics updates on CAR T pipeline; shifts focus to CTX112/CTX131, CTX110 Part B shows 23% 6-month CR","bullets":["Next-generation candidates CTX112 (CD19) and CTX131 (CD70) incorporate knock-out of Regnase-1 and TGFBR2 to enhance potency.","Emerging data show CTX112 and CTX131 achieve significantly higher CAR T expansion and functional persistence in patients vs. first-gen.","CTX110 Phase 1/2 Part B reported increased 6-month complete response rate of 23%, up from 19% in Part A.","Company will transition CTX110 and CTX130 patients to long-term follow-up; CTX112 and CTX131 trials ongoing.","Internal GMP facility manufacturing CTX112 and CTX131 for clinical trials; manufacturing robustness improved."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-067774","json":"https://secwatch.observer/filing/0000950170-23-067774.json","markdown":"https://secwatch.observer/filing/0000950170-23-067774.md","text":"https://secwatch.observer/filing/0000950170-23-067774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023067774/0000950170-23-067774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023067774/crsp-20231204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T18:47:02.232569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}